Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

A role for exogenous GLP-1 in the management of postprandial hypoglycaemia after Roux-en-Y gastric bypass?

Research output: Contribution to journalComment/debateResearchpeer-review

DOI

  1. Risk factors for hyperglycemia in pregnancy in the DALI study differ by period of pregnancy and OGTT time point

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. EJE PRIZE 2018: A gut feeling about glucagon

    Research output: Contribution to journalReviewpeer-review

  3. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. SGLT2 inhibitors: Clinical benefits by restoration of normal diurnal metabolism?

    Research output: Contribution to journalReviewpeer-review

  1. Reduced erythrocyte lifespan measured by chromium-51 in patients with type 2 diabetes undergoing long-term hemodialysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Prognostic factors of 90-day mortality in patients hospitalised with COVID-19

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Roux-en-Y gastric bypass (RYGB) is one of the most common bariatric surgeries. The procedure induces a sustained weight loss together with a reduction in obesity-related comorbidities including type 2 diabetes. The effects on postprandial glucose metabolism are evident within days or weeks after surgery - before any weight loss has occurred - and are thought to be achieved by a faster passage of nutrients to the small intestine and ensuing alterations in the secretion of several gastrointestinal hormones, acceleration of glucose absorption and increased insulin secretion. Especially the remarkable increase in postprandial plasma levels of the gut-derived incretin hormone glucagon-like peptide 1 (GLP-1) - with not only a potent insulinotropic effect, but also a glucagonostatic effect - is believed to contribute to the metabolic improvements and the early remission of type 2 diabetes seen after RYGB.

Original languageEnglish
JournalEuropean Journal of Endocrinology
Volume181
Issue number3
Pages (from-to)5-8
Number of pages4
ISSN0804-4643
DOIs
Publication statusPublished - Jul 2019

ID: 58138553